Adults with congenital heart disease benefit from routine care at ACHD centers and collaboration with ACHD cardiologists ...

Diagnostic evaluation should follow principle of 'as low as reasonably achievable'; systemic therapy should be deferred until second trimester ...

In modified intention-to-treat analysis, time to linkage to care significantly less for people with HIV in intervention group ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

The Food and Drug Administration (FDA) has approved Wegovy ® (semaglutide) tablets, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity.

Pediatric patients aged 10 years and older with iron deficiency may now be treated with Accrufer following an expanded FDA approval.

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Ceralasertib is an oral selective inhibitor of the ATR kinase, an important DNA-repairing protein in tumor cells.

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

(HealthDay News) — The US Food and Drug Administration (FDA) is weighing a change that could make warning labels on dietary supplements appear less often on packaging. Unlike prescription drugs, ...

Vaccination linked to lower risk for hospitalization, critical care unit admission, preterm birth during delta and omicron periods ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.